Target Price | $73.44 |
Price | $23.70 |
Potential |
209.87%
register free of charge
|
Number of Estimates | 17 |
17 Analysts have issued a price target Janux Therapeutics Inc 2026 .
The average Janux Therapeutics Inc target price is $73.44.
This is
209.87%
register free of charge
$210.00
786.08%
register free of charge
$25.25
6.54%
register free of charge
|
|
A rating was issued by 21 analysts: 20 Analysts recommend Janux Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2026 of
209.87%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 10.59 | 2.35 |
31.06% | 77.77% | |
EBITDA Margin | -913.98% | -7,476.39% |
3.98% | 718.01% | |
Net Margin | -651.46% | -5,845.61% |
9.70% | 797.30% |
16 Analysts have issued a sales forecast Janux Therapeutics Inc 2025 . The average Janux Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Janux Therapeutics Inc EBITDA forecast 2025. The average Janux Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Janux Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Janux Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.28 | -2.32 |
3.03% | 81.25% | |
P/E | negative | |
EV/Sales | 200.80 |
18 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Janux Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
Stifel |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Jul 11 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Analyst Rating | Date |
---|---|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
Locked
Stifel:
Locked
➜
Locked
|
Sep 10 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Sep 10 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 04 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Jul 11 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.